<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

CNV 1014802 - GSK 1014802 | GSK2 | Raxatrigine | BIIB 074 | Vixotrigine

產(chǎn)品貨號

Axon 1899 CAS [934240-30-9] MF C18H19FN2O2MW 314.35 Purity: 99% Optical purity: Optically pure Soluble in 0.1N HCl(aq) and DMSO Description Sodium channel blocker with potent anticonvulsant activity; potential for novel treatment for Schizophrenia.?CNV 1014802 (GSK 1014802 or GSK2 or?Raxatrigine) was tested in clinical trials for treatment of trigeminal neuralgia, and shows selectivity for the Nav1.7 subtype over the other subtypes tested (Nav1.1, Nav1.2, Nav1.3, Nav1.5, Nav1.6 and TTX-R), for both the resting and depolarized states. The water soluble HCl salt of CNV 1014802 (Axon 2548) is available as well KEYWORDS: CNV 1014802 | supplier | Na+ channel blocker | GSK 1014802 | GSK2 | Raxatrigine | BIIB 074 | Vixotrigine | CNV1014802 | CNV-1014802 | GSK1014802 | GSK-1014802 | GSK 2 | GSK-2 | BIIB074 | BIIB-074 | CAS [934240-30-9] | Sodium | Nav1.7 | Nav1.2 | Nav1.6 | Nav1.3 | Blocker | Ion Channels | anticonvulsant | Schizophrenia | trigeminal neuralgia | neuropathic | pain

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

CNV 1014802 - GSK 1014802 | GSK2 | Raxatrigine | BIIB 074 | Vixotrigine

Based on 56 reference(s) in Google Scholar 9 10 56

Axon 1899

CAS [934240-30-9]

MF C18H19FN2O2
MW 314.35

Purity: 99%
Optical purity: Optically pure
Soluble in 0.1N HCl(aq) and DMSO

CNV 1014802

Description

Sodium channel blocker with potent anticonvulsant activity; potential for novel treatment for Schizophrenia.?CNV 1014802 (GSK 1014802 or GSK2 or?Raxatrigine) was tested in clinical trials for treatment of trigeminal neuralgia, and shows selectivity for the Nav1.7 subtype over the other subtypes tested (Nav1.1, Nav1.2, Nav1.3, Nav1.5, Nav1.6 and TTX-R), for both the resting and depolarized states.

The water soluble HCl salt of CNV 1014802 (Axon 2548) is available as well

KEYWORDS: CNV 1014802 | supplier | Na+ channel blocker | GSK 1014802 | GSK2 | Raxatrigine | BIIB 074 | Vixotrigine | CNV1014802 | CNV-1014802 | GSK1014802 | GSK-1014802 | GSK 2 | GSK-2 | BIIB074 | BIIB-074 | CAS [934240-30-9] | Sodium | Nav1.7 | Nav1.2 | Nav1.6 | Nav1.3 | Blocker | Ion Channels | anticonvulsant | Schizophrenia | trigeminal neuralgia | neuropathic | pain

CH Large et al. The efficacy of sodium channel blockers to prevent phencyclidine-induced cognitive dysfunction in the rat: potential for novel treatments for schizophrenia. J. Pharmacol. Exp. Ther. 2011, 338(1), 100-113.?

J.M. Zakrzewska et al. Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients ith trigeminal neuralgia. Trials. 2013 Nov 23;14:402.

A. Nardi et al. Advances in targeting voltage-gated sodium channels with small molecules. ChemMedChem. 2012 Oct;7(10):1712-40.

C.H. Large et al. The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res. 2009 Jul;85(1):96-106.

JR Deuis et al. Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain. Toxins (Basel). 2016 Mar 17;8(3). pii: E78.

Certificate of Analysis
Material Safety Data Sheet

CNS Pain & Inflammation Nav1.7 Unclassified Nav1.2 Nav1.6 Nav1.3

Na+ channel blocker; anti-convulsant

Chemical name

(2S,5R)-5-(4-(2-fluorobenzyloxy)phenyl)pyrrolidine-2-carboxamide

Parent CAS No.

[934240-30-9]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>